`
`———————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`———————
`
`ETON PHARMACEUTICALS, INC.,
`
`Petitioner
`
`v.
`
`EXELA PHARMA SCIENCES, LLC,
`
`Patent Owner
`
`———————
`
`U.S. PATENT NO. 10,583,155
`
`
`DECLARATION OF JUDY K. HE
`
`
`
`
`
`
`
`Eton Ex. 1105
`1 of 4
`
`
`
`1. My name is Judy He. I am over 21 years of age. I am an attorney at
`
`Haynes and Boone, LLP, representing Eton Pharmaceuticals, Inc. (hereinafter
`
`“Eton”) in connection with the above-captioned matter. I submit this declaration
`
`upon my personal knowledge in support of Eton’s Petition for Post Grant Review of
`
`U.S. Patent No. 10,583,155.
`
`2.
`
`On May 28, 2020, I accessed https://beta.regulations.gov and searched
`
`for “fda-2018-p-1808”. I received five results under the “Documents” tab (also
`
`available at https://beta.regulations.gov/search?filter=fda-2018-p-1808), and I
`
`downloaded each of them, including:
`
`a. Citizen Petition from Lachman Consultant Services, Inc;
`
`b. Attachment 1 Orange Book re Citizen Petition from Lachman
`
`Consultant Services, Inc;
`
`c. Attachment 2 Proposed Labeling re Citizen Petition from Lachman
`
`Consultant Services, Inc;
`
`d. Attachment 3 Approved Labeling for Reference Listed Drug re
`
`Citizen Petition from Lachman Consultant Services, Inc; and
`
`e. Acknowledgment Letter from FDA DDM to Lachman Consultant
`
`Services, Inc
`
`3.
`
`Pages 1 to 3 of Exhibit 1092 is a true and correct copy of the above-
`
`referenced “Citizen Petition from Lachman Consultant Services, Inc,” that I
`
`2
`
`Eton Ex. 1105
`2 of 4
`
`
`
`downloaded on May 28, 2020 from https://beta.regulations.gov/document/FDA-
`
`2018-P-1808-0001.
`
`4.
`
`Page 4 of Exhibit 1092 is a true and correct copy of the above-
`
`referenced “Attachment 1 Orange Book re Citizen Petition from Lachman
`
`Consultant Services, Inc,”
`
`that I downloaded on May 28, 2020 from
`
`https://beta.regulations.gov/document/FDA-2018-P-1808-0003.
`
`5.
`
`Pages 5 to 6 of Exhibit 1092 is a true and correct copy of the above-
`
`referenced “Attachment 2 Proposed Labeling re Citizen Petition from Lachman
`
`Consultant Services, Inc,”
`
`that I downloaded on May 28, 2020 from
`
`https://beta.regulations.gov/document/FDA-2018-P-1808-0004.
`
`6.
`
`Pages 7 to 11 of Exhibit 1092 is a true and correct copy of the above-
`
`referenced “Attachment 3 Approved Labeling for Reference Listed Drug re Citizen
`
`Petition from Lachman Consultant Services, Inc,” that I downloaded on May 28,
`
`2020 from https://beta.regulations.gov/document/FDA-2018-P-1808-0005.
`
`7.
`
`Page 12 of Exhibit 1092 is a true and correct copy of the above-
`
`referenced “Acknowledgment Letter from FDA DDM to Lachman Consultant
`
`Services,
`
`Inc,”
`
`that
`
`I
`
`downloaded
`
`on May
`
`28,
`
`2020
`
`from
`
`https://beta.regulations.gov/document/FDA-2018-P-1808-0002.
`
`8.
`
`I hereby declare under penalty of perjury under the laws of the United
`
`States of America that the foregoing is true and correct, and that all statements made
`
`3
`
`Eton Ex. 1105
`3 of 4
`
`
`
`of my own knowledge are true and that all statements made on information and belief
`
`are believed to be true. I understand that willful false statements are punishable by
`
`fine or imprisonment or both. See 18 U.S.C. § 1001.
`
`Date:
`
`7 20
`
`Respectfully submitted,
`
`Judy K. He
`
`Eton Ex. 1105
`4 of 4
`
`Eton Ex. 1105
`4 of 4
`
`